SOAT1在糖尿病肾病与Alport综合征中促进胆固醇酯蓄积
缺陷胆固醇代谢与糖尿病肾病和Alport综合征进展相关,但游离或酯化胆固醇蓄积的作用不明。研究显示抑制SOAT1可减少人足细胞胆固醇酯和脂滴形成,减轻脂毒性足细胞损伤,并增加ABCA1表达和胆固醇外流。Soat1缺陷小鼠10-12月龄未出现白蛋白尿或系膜扩张,在疾病模型中SOAT1缺陷/抑制减少肾皮质胆固醇酯并保护进展。
要点
- 抑制SOAT1减少足细胞胆固醇酯和脂滴形成,减轻脂毒性损伤。
- SOAT1缺陷/抑制在糖尿病肾病和Alport综合征模型中保护疾病进展。
- 靶向SOAT1介导的胆固醇代谢或为治疗新策略。
核心结论
- 靶向SOAT1介导的胆固醇代谢可能成为治疗糖尿病肾病和Alport综合征的新策略。
研究设计与样本
- 研究采用人足细胞体外实验及Soat1缺陷小鼠和糖尿病肾病、Alport综合征实验模型。
主要发现
- 抑制SOAT1减少人足细胞胆固醇酯和脂滴形成,并减轻脂毒性足细胞损伤。
- SOAT1抑制增加ABCA1表达和ABCA1介导的胆固醇外流。
- Soat1缺陷小鼠10-12月龄未出现白蛋白尿或系膜扩张。
- 在糖尿病肾病和Alport综合征模型中,SOAT1缺陷/抑制减少肾皮质胆固醇酯含量并保护疾病进展。
临床怎么用
- SOAT1抑制可能作为糖尿病肾病和Alport综合征的潜在治疗方向,但尚需临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Defective cholesterol metabolism primarily linked to reduced ATP-binding cassette transporter A1 (ABCA1) expression is closely associated with the pathogenesis and progression of kidney diseases, including diabetic kidney disease and Alport Syndrome. However, whether the accumulation of free or esterified cholesterol contributes to progression in kidney disease remains unclear. Here, we demonstrate that inhibition of sterol-O-acyltransferase-1 (SOAT1), the enzyme at the endoplasmic reticulum that converts free cholesterol to cholesterol esters, which are then stored in lipid droplets, effectively reduced cholesterol ester and lipid droplet formation in human podocytes. Furthermore, we found that inhibition of SOAT1 in podocytes reduced lipotoxicity-mediated podocyte injury in diabetic kidney disease and Alport Syndrome in association with increased ABCA1 expression and ABCA1-mediated cholesterol efflux. In vivo, Soat1 deficient mice did not develop albuminuria or mesangial expansion at 10-12 months of age. However, Soat1 deficiency/inhibition in experimental models of diabetic kidney disease and Alport Syndrome reduced cholesterol ester content in kidney cortices and protected from disease progression. Thus, targeting SOAT1-mediated cholesterol metabolism may represent a new therapeutic strategy to treat kidney disease in patients with diabetic kidney disease and Alport Syndrome, like that suggested for Alzheimer's disease and cancer treatments.
引用
- Liu X, Ducasa GM, Mallela SK, et al. Sterol-O-acyltransferase-1 has a role in kidney disease associated with diabetes and Alport syndrome. Kidney Int. 2020. PMID: 32739420. doi:10.1016/j.kint.2020.06.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。